Business Wire

HAI-ROBOTICS

27.12.2021 10:09:04 CET | Business Wire | Press release

Share
HAI ROBOTICS Celebrates 5th Anniversary, Gets AI Unicorn Nomination by Hurun Report

HAI ROBOTICS , a global leader in Autonomous Case-handling Robotics (ACR) systems for warehouse order fulfillment, is celebrating its fifth anniversary at its new headquarters as it ranks among global unicorns according to this year’s unicorn ranking list from the Hurun Research Institute.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211226005013/en/

The company, a logistics warehousing automation solution provider that secured three rounds of funding in 2021, was nominated along with 300 other Chinese start-ups which were valued at more than US$1 billion as of November this year in a global list totaling 1,058. The list was released last week.

HAI ROBOTICS was founded in late 2016 by a group of like-minded robot enthusiasts who aspire to create value for every warehouse and factory with the vision to push forward human civilization through robotics technology. The company’s birth originated from a revolutionary idea that took shape as early as 2015 – the totes-to-person solution – to improve warehouse operational efficiency, instead of creating a homogenous brand of the then prevalent shelves-to-person material handling.

The solution underwent repeated tests and trials in a real warehouse environment for nearly two years before it was formally introduced into the market. The company’s first project was successfully deployed in Best Logistics’ warehouse in August 2018. Soon the story went viral with great exemplary effect that the ACR solution swiftly secured footholds in factories and warehouses.

“It’s an extraordinary journey for us to grow from the cradle of a small workshop into a company of more than 1,200 employees with five branch offices across the globe today,” said Richie Chen, the company’s founder and CEO. “We’re celebrating our fifth anniversary with gratitude to our customers and investors for their trust and confidence in our team. We’ll keep making innovative products and stay committed to bringing value to our partners.”

Automating a warehouse can be a huge project worthy of careful consideration for any business operator. The concerns could range from the length of necessary deployment time, agility of refitting, affordability to ROIs. The HAI ROBOTICS team kept their users’ concerns in mind when building their products. Hence, they kept refining their ideas and fine-tuning the HAIPICK robots for wider applications and stricter storage requirements.

First and foremost, the HAIPICK ACR solution allows greater space utilization and higher goods-handling precision and efficiency than traditional Goods-to-Person solutions, such as Kiva robots that move an entire rack. With the HAIPICK ACR solution, a warehouse’s storage density can be boosted by 80% to 400% and a worker’s picking speed can be improved 3 to 4 times. In addition, the HAIPICK robots, using QR codes on the floor for navigation, can be deployed within one month with no altering of the interior structure of a warehouse.

Thanks to its easy deployment and flexibility, the solution has been adopted by a wide array of customers who prefer smaller picking units than an entire rack or pallet when automating their warehouses. So far, HAI ROBOTICS has been running more than 300 projects globally in various fields, including e-commerce, 3PL, apparel, electronics, energy, manufacturing, medicine, and more. To provide localized service overseas, it has partnered with dozens of global logistics and supply chain leaders, including LG CNS, MHS, MUJIN, BPS, Savoye, Invar, SSI Schaefer and more.

About HAI ROBOTICS

HAI ROBOTICS, a trailblazer of Autonomous Case-handling Robot (ACR) systems, is committed to providing efficient, intelligent, flexible, and customized warehouse automation solutions through robotics technology and AI algorithms. It aims to create value for each factory and logistics warehouse.

The HAIPICK ACR system, independently developed in 2015, is the world's first of its kind.

Founded in 2016 with headquarters in Shenzhen, China, HAI ROBOTICS has set up five subsidiaries in Hong Kong SAR, Japan, Singapore, the U.S. and the Netherlands, serving customers from more than 30 countries and regions. It now has over 1,200 staff, more than 50% of whom are engineers. The company has acquired more than 600 global patents for core intellectual properties involving positioning, robot control and warehouse management. In the latest C and D rounds of funding in 2021, the company raised over US$200 million in total.

Link:

ClickThru

Social Media:

https://www.facebook.com/HAIROBOTICS/videos/?ref=page_internal

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye